Technology area: Biotechnology & Pharmaceuticals
18 pending office actions • 7 art units • 18 examiners • 0 of 18 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Editas Medicine Inc. has 17 pending office actions in Biotechnology & Pharmaceuticals. The docket uses 17 examiners across 7 art units, so each matter has a distinct examiner assignment within a more limited unit structure.
MEAH, MOHAMMAD Y is the busiest examiner, with 1 pending matter. Counsel can organize the portfolio by art unit and technical subject while handling examiner interactions independently.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (17%) |
| §103 only | 3 (17%) |
| §102 only | 1 (6%) |
| Double-patenting only | 1 (6%) |
| Double-patenting + other | 4 (22%) |
| Multi-statute (no §101) | 6 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEAH, MOHAMMAD Y | 1 | 70.7% | +42.8% |
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
| ROGERS, ERIC JASON | 1 | 56.9% | +33.2% |
| HUDSON, AMY ROSE | 1 | 74.8% | +11.7% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| HASAN, KHALEDA B | 1 | 59.3% | +49.0% |
| CHONG, KIMBERLY | 1 | 72.3% | +13.1% |
| GONZALES, JOSEPHINE MARIA | 1 | 28.8% | +34.6% |
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
| DHAR, MATASHA | 1 | 43.5% | +44.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786753 | ENGINEERED CELLS FOR THERAPY | GONZALES, JOSEPHINE MARIA | 66d overdue |
| 17572403 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | SINGH, ANOOP KUMAR | 53d overdue |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | ROGERS, ERIC JASON | 30d overdue |
| 16093334 | GRNA FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | RYAN, DOUGLAS CHARLES | 40d |
| 19541682 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR) | MEAH, MOHAMMAD Y | — |
| 18394385 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | KONOPKA, CATHERINE ANNE | — |
| 18468681 | NOVEL RECOMBINASES AND METHODS OF USE | YU, DELPHINUS DOU YI | — |
| 16899302 | CPF1-RELATED METHODS AND COMPOSITIONS FOR GENE EDITING | WESTON, ALYSSA G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17666390 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | DHAR, MATASHA | 92d overdue |
| 18059213 | SYSTEMS AND METHODS FOR TREATING ALPHA 1-ANTITRYPSIN (A1AT) DEFICIENCY | CHONG, KIMBERLY | 70d overdue |
| 17786753 | ENGINEERED CELLS FOR THERAPY | GONZALES, JOSEPHINE MARIA | 66d overdue |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | ROGERS, ERIC JASON | 30d overdue |
| 19541682 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR) | MEAH, MOHAMMAD Y | — |
| 18394385 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | KONOPKA, CATHERINE ANNE | — |
| 18555716 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | HUDSON, AMY ROSE | — |
| 18104461 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | HASAN, KHALEDA B | — |
| Art Unit | Apps |
|---|---|
| 1636 | 6 |
| 1638 | 3 |
| 1632 | 3 |
| 1633 | 2 |
| 1635 | 2 |
| 1652 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19541682 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR) | MEAH, MOHAMMAD Y | 1652 | §103§112 | Non-Final OA | — | Pending | Feb 17, 2026 |
| 18394385 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | KONOPKA, CATHERINE ANNE | 1636 | §101§103§112Other | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | ROGERS, ERIC JASON | 1638 | §103§112 | Final Rejection | 30d overdue | Pending | Dec 12, 2023 |
| 18555716 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | HUDSON, AMY ROSE | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Oct 16, 2023 |
| 18468681 | NOVEL RECOMBINASES AND METHODS OF USE | YU, DELPHINUS DOU YI | 1636 | §102§112 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18104461 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | HASAN, KHALEDA B | 1636 | §102Other | Non-Final OA | — | Pending | Feb 01, 2023 |
| 18059213 | SYSTEMS AND METHODS FOR TREATING ALPHA 1-ANTITRYPSIN (A1AT) DEFICIENCY | CHONG, KIMBERLY | 1636 | §103 | Final Rejection | 70d overdue | Pending | Nov 28, 2022 |
| 17786753 | ENGINEERED CELLS FOR THERAPY | GONZALES, JOSEPHINE MARIA | 1638 | §102§103 | Non-Final OA | 66d overdue | Pending | Jun 17, 2022 |
| 17836165 | OPTIMIZED CRISPR/CAS9 SYSTEMS AND METHODS FOR GENE EDITING IN STEM CELLS | MONTANARI, DAVID A | 1632 | DP | Non-Final OA | — | Pending | Jun 09, 2022 |
| 17666390 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | DHAR, MATASHA | 1632 | §103Other | Final Rejection | 92d overdue | Pending | Feb 07, 2022 |
| 17572403 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | 53d overdue | Pending | Jan 10, 2022 |
| 17533007 | EVALUATION OF CAS9 MOLECULE/GUIDE RNA MOLECULE COMPLEXES | LEITH, NANCY J | 1636 | §103Other | Non-Final OA | 28d | Pending | Nov 22, 2021 |
| 17412608 | CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY | BABIC, CHRISTOPHER M | 1633 | §103DP | Final Rejection | — | Pending | Aug 26, 2021 |
| 17433975 | CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP) | SULLIVAN, STEPHANIE LAUREN | 1635 | §103DP | Final Rejection | 114d overdue | Pending | Aug 25, 2021 |
| 17430382 | MODIFIED NATURAL KILLER (NK) CELLS FOR IMMUNOTHERAPY | GRABER, JAMES J | 1631 | §102§103§112DP | Final Rejection | 56d overdue | Pending | Aug 12, 2021 |
| 16899302 | CPF1-RELATED METHODS AND COMPOSITIONS FOR GENE EDITING | WESTON, ALYSSA G | 1633 | §102§103§112 | Non-Final OA | — | Pending | Jun 11, 2020 |
| 16098845 | GENETICALLY ENGINEERED CELLS AND METHODS OF MAKING THE SAME | VIVLEMORE, TRACY ANN | 1638 | §101§103§112 | Final Rejection | — | Pending | Nov 02, 2018 |
| 16093334 | GRNA FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | RYAN, DOUGLAS CHARLES | 1635 | §101§103§112 | Non-Final OA | 40d | Pending | Oct 12, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEditas Medicine Inc. has 18 pending office actions as of October 2026, spread across 7 art units and 18 examiners.
Mohammad Y Meah has the most, with 1 of Editas Medicine Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
